Back to search results

Observational Study of a Modified Resectoscope for Bladder Cancer

This observational study is looking at a modified resectoscope (a surgical tool) used after a cystectomy (surgical removal of the bladder). The goal is to see if this modified device can provide better information about bladder tumors compared to the standard TURBT (transurethral resection of bladder tumors) procedure. Researchers want to know if the modified resectoscope helps doctors get more complete tumor samples, including all tissue layers, which could improve understanding of the cancer. You may be able to join if you are 18 or older and need your bladder removed at the NIH Clinical Center. This study is currently unclear on its recruitment status and plans to enroll 25 participants.

Study design
This is an observational study involving 25 participants. It compares a modified resectoscope to the standard TURBT procedure.
What's involved
You will receive routine surgical transurethral resection of bladder tumors (TURBT). The modified resectoscope will be used on your removed bladder specimen after surgery.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, assessment of the resectoscope modification, will be measured at the time of surgery/pathologic assessment (7-10 days).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04235764

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Recruiting
Not specifiedAges 18+Observational
National Cancer Institute (NCI)
~25 participants
Updated 2026-09-08 on ClinicalTrials.gov
What's tested:modified resectoscopeTURBT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assessment of resectoscope device modification on pathologic standards for the TURBT procedure
Measured over Time of surgery/pathologic assessment (7-10 days)

Conditions

Bladder Cancer

Explore related trials

Bladder Carcinoma

NCT04235764

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • National Institutes of Health Clinical Center

    Bethesda, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Raju R Chelluri, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

NCI Medical Oncology Referral Office
[email protected]
(240) 760-6050
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients requiring surgical removal of the bladder at the NIH Clinical Center.
Men and women
Age greater than or less than 18 years
Deemed clinically appropriate for the planned surgical procedure.
Ability of subject to understand and the willingness to sign a written informed consent document.
Subjects will be asked to co-enroll in 15-C-0087, "Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens from Healthy Volunteers and Urothelial Cancer Patients." NOTE: Most participants are expected to already be enrolled in 15-C-0087 prior to entry in this study.

What this trial measures

  • Assessment of resectoscope device modification on pathologic standards for the TURBT procedureTime of surgery/pathologic assessment (7-10 days)

    -Presence of three tissue layers with in the tumor specimens containing bladder mucosa, lamina propria, and portions of the muscularis.-Information regarding tumor margin, assessed as the ability to ascertain if tumor is present at the margin of the resection.